Chemistry:ONO-2020
From HandWiki
ONO-2020 is an epigenetic modulator, immunomodulator, and possible cognitive enhancer which is under development for the treatment of agitation including due to Alzheimer's disease.[1][2][3][4] It is taken orally.[1] The drug's exact mechanism of action or biological target does not yet appear to have been disclosed.[1][2][3][4] ONO-2020 is under development by Ono Pharmaceutical.[1][2][3][4] As of May 2025, it is in phase 2 clinical trials for treatment of agitation and Alzheimer's disease.[1][2][3][4] The chemical structure of ONO-2020 does not yet appear to have been disclosed.[1]
See also
- List of investigational agitation drugs
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 "ONO 2020". 12 May 2025. https://adisinsight.springer.com/drugs/800069840.
- ↑ 2.0 2.1 2.2 2.3 "Delving into the Latest Updates on ONO-2020 with Synapse". 3 June 2025. https://synapse.patsnap.com/drug/4d9da8a63ee842399d0f1726c920b41c.
- ↑ 3.0 3.1 3.2 3.3 "ONO-2020 Drug Profile". 1 January 1900. https://pryzm.ozmosi.com/product/26925.
- ↑ 4.0 4.1 4.2 4.3 "Alzheimer's disease drug development pipeline: 2026". Alzheimer's & Dementia (New York, N. Y.) 12 (2). 2026. doi:10.1002/trc2.70251. PMID 42095064.
